What are the limitations of using olaparib and bevacizumab for ovarian cancer?
Olaparib (a PARP inhibitor) and bevacizumab (an anti-angiogenic drug) are used together as maintenance therapy for advanced ovarian cancer. However, this combination has important limitations. It works best in patients whose tumors have a specific DNA repair defect called homologous recombination deficiency (HRD). In patients without HRD, the benefit is much smaller. Other limitations include side effects, development of drug resistance, and high cost. Understanding these limitations helps you and your doctor decide if this treatment is right for you.
What the research says
The PAOLA-1 trial showed that adding olaparib to bevacizumab significantly improved progression-free survival and overall survival in patients with HRD-positive advanced ovarian cancer, but not in those without HRD 9. In HRD-positive patients, 5-year progression-free survival was 35% with the combination versus 15% with bevacizumab alone 9. However, for patients with homologous recombination-proficient (HRP) tumors, the benefit is limited 10. A 2024 study found that bevacizumab can increase olaparib sensitivity in HRP cells by suppressing a protein called CRY1, but this effect may not be strong enough in all patients 10. Resistance to PARP inhibitors is another limitation; mechanisms include changes in DNA repair pathways and tumor microenvironment factors 2. The combination also carries risks of side effects such as high blood pressure, fatigue, and gastrointestinal issues, and requires careful monitoring 9. Additionally, the high cost of these drugs can be a barrier for some patients.
What to ask your doctor
- What is my tumor's HRD status, and how does that affect whether olaparib plus bevacizumab is a good option for me?
- What are the most common side effects of this combination, and how can they be managed?
- Are there alternative treatments if I cannot tolerate or do not benefit from olaparib and bevacizumab?
- How long would I need to stay on this treatment, and what monitoring is required?
- What are the costs, and does my insurance cover this combination therapy?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.